Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone

NCT00359424 is registered in ClinicalTrials.gov with Joseph Broderick as lead sponsor.

NCT NCT00359424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00359424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone
Lead sponsor
Joseph Broderick
Phase
Phase 3
Overall status
Terminated
Start date
August 31, 2006
Completion date
April 30, 2013
Enrollment
656 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

stroke